MEASURING OF THE UNCERTAINTY IN REIMBURSEMENT SYSTEM FOR MEDICINAL PRODUCTS
Author(s)
Araja D
Riga Stradins University, Riga, Latvia
OBJECTIVES: Promoting access to innovative, safe and effective medicinal products is defined as a priority of pharmaceutical policy in the European Union. At the same time, the inclusion of medicinal products in the schemes of early marketing authorisation and reimbursement should be further clarified in order to improve transparency and reduce uncertainty. The aim of this policy research was to identify the possibilities to measure the reduction of uncertainties in reimbursement system for medicinal products. METHODS: The research was based on the literature review on topics of definitions, taxonomy and measuring of the uncertainty in health care, as well as conditions of the reimbursement system for medicinal products in Latvia. RESULTS: The reimbursement system in Latvia operates under strictly limited financial resources; therefore a wide spectrum of financial tools has been implemented. Managed entry agreements, which are one of these tools, limit the uncertainties regarding to clinical and economic evidence of new medicines, fair price and budget impact, as well as eligible patients’ population. At the same time the decision making should be supported by the evidence of the real reduction of uncertainties. Different concepts and taxonomies relating to uncertainty in decision modelling exist, including stochastic, parameter and structural uncertainty. However, the methods of measuring uncertainties in models are not fully suitable to estimate the reduction of uncertainty around the clinical effectiveness and efficiency of a medicinal product in real life. CONCLUSIONS: Measuring of uncertainties is an important issue that has attracted by increasing attention in light of supporting the schemes of early marketing authorisation of medicinal products and their inclusion in reimbursement systems. The measures of uncertainties used in decision modelling should be adapted to flexible use in real life conditions.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PHP129
Topic
Economic Evaluation, Health Policy & Regulatory
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Reimbursement & Access Policy, Risk-sharing Approaches
Disease
Multiple Diseases